
|Articles|September 1, 2003
ENBREL Indication Expanded
The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
AI Analysis Reveals Menopausal Hair Loss Linked to Systemic Health and Inflammation
3
Dual-Action Microneedle Patch Shows Promise for Psoriasis in Preclinical Study
4
Novel Botanical Moisturizer Demonstrates Superior Efficacy Over Metronidazole in Phase 2 Rosacea Trial
5














